These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28577044)

  • 1. Successful treatment with azacitidine for the simultaneous occurrence of multiple myeloma and acute myeloid leukemia with concomitant del(5q) and the JAK2 V617F mutation.
    Oka S; Ono K; Nohgawa M
    Ann Hematol; 2017 Aug; 96(8):1411-1413. PubMed ID: 28577044
    [No Abstract]   [Full Text] [Related]  

  • 2. Myelodysplastic syndrome with del (5q) and JAK2(V617F) mutation transformed to acute myeloid leukaemia with complex karyotype.
    Pich A; Godio L; Riera L; Cavaliere C; Kerim S; Bonello L; Francia di Celle P
    Ann Hematol; 2016 Feb; 95(3):525-7. PubMed ID: 26750119
    [No Abstract]   [Full Text] [Related]  

  • 3. Myelodysplastic syndrome with concomitant del(5q) and JAK2 V617F mutation transformed to acute myeloid leukemia with an additional chromosomal abnormality after a long-term treatment with lenalidomide.
    Oka S; Ono K; Nohgawa M
    Leuk Lymphoma; 2017 Oct; 58(10):2511-2513. PubMed ID: 28278708
    [No Abstract]   [Full Text] [Related]  

  • 4. Simultaneous occurrence of two distinct leukemic clones with PML-RARα and RUNX1-RUNX1T1 in a case of acute myeloid leukemia.
    Shao H; Yang Q; Zhang P; Liu H; Wu C; Cen J; Qiu H; Chen S; Pan J
    Ann Hematol; 2018 Mar; 97(3):529-531. PubMed ID: 29124313
    [No Abstract]   [Full Text] [Related]  

  • 5. JAK2 V617F mutation is associated with 5q- syndrome in Chinese.
    Wong KF; Wong WS; Siu LL; Lau TC; Chan NP
    Leuk Lymphoma; 2009 Aug; 50(8):1333-5. PubMed ID: 19562618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study.
    Platzbecker U; Braulke F; Kündgen A; Götze K; Bug G; Schönefeldt C; Shirneshan K; Röllig C; Bornhäuser M; Naumann R; Neesen J; Giagounidis A; Hofmann WK; Ehninger G; Germing U; Haase D; Wermke M
    Leukemia; 2013 Jun; 27(6):1403-7. PubMed ID: 23354011
    [No Abstract]   [Full Text] [Related]  

  • 7. Decitabine treatment of multiple extramedullary acute myeloid leukemia involvements after essential thrombocytemia transformation.
    Niscola P; Abruzzese E; Trawinska MM; Palombi M; Tendas A; Giovannini M; Scaramucci L; Cupelli L; Fratoni S; Noguera NI; Catalano G; de Fabritiis P
    Acta Oncol; 2017 Oct; 56(10):1331-1333. PubMed ID: 28488914
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
    Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
    Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
    [No Abstract]   [Full Text] [Related]  

  • 9. Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.
    Woo J; Howard NP; Storer BE; Fang M; Yeung CC; Scott BL; Deeg HJ
    Haematologica; 2017 Jun; 102(6):e216-e218. PubMed ID: 28209655
    [No Abstract]   [Full Text] [Related]  

  • 10. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.
    Sokol L; Caceres G; Rocha K; Stockero KJ; Dewald DW; List AF
    Leuk Res; 2010 Jun; 34(6):821-3. PubMed ID: 19819015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The 5q deletion size in myeloid malignancies is correlated to additional chromosomal aberrations and to TP53 mutations.
    Stengel A; Kern W; Haferlach T; Meggendorfer M; Haferlach C
    Genes Chromosomes Cancer; 2016 Oct; 55(10):777-85. PubMed ID: 27218649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
    Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
    Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Case of Leukemia Cutis with Acute Myeloid Leukemia on Azacitidine Therapy.
    Kara A; Akın Belli A; Karakuş V; Dere Y; Kurtoğlu E
    Turk J Haematol; 2017 Jun; 34(2):192-193. PubMed ID: 28183685
    [No Abstract]   [Full Text] [Related]  

  • 14. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts.
    Kadia TM; Thomas XG; Dmoszynska A; Wierzbowska A; Minden M; Arthur C; Delaunay J; Ravandi F; Kantarjian H
    Am J Hematol; 2015 Jul; 90(7):E139-41. PubMed ID: 25858582
    [No Abstract]   [Full Text] [Related]  

  • 16. [Effective azacitidine treatment for myelodysplastic syndrome transformed from essential thrombocythemia].
    Iizuka H; Yoshimi A; Yamamoto G; Masuda A; Nannya Y; Ichikawa M; Yatomi Y; Kurokawa M
    Rinsho Ketsueki; 2013 May; 54(5):468-72. PubMed ID: 23727686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK2 V617F mutation identifies a subgroup of MDS patients with isolated deletion 5q and a proliferative bone marrow.
    Ingram W; Lea NC; Cervera J; Germing U; Fenaux P; Cassinat B; Kiladjian JJ; Varkonyi J; Antunovic P; Westwood NB; Arno MJ; Mohamedali A; Gaken J; Kontou T; Czepulkowski BH; Twine NA; Tamaska J; Csomer J; Benedek S; Gattermann N; Zipperer E; Giagounidis A; Garcia-Casado Z; Sanz G; Mufti GJ
    Leukemia; 2006 Jul; 20(7):1319-21. PubMed ID: 16617322
    [No Abstract]   [Full Text] [Related]  

  • 18. Coincidence of 5q deletion and the JAK2V617F mutation: report of two patients with overlapping myelodysplastic and myeloproliferative features and review of the literature.
    Bürki S; Shumilov E; Bonadies N; Flach J; Legros M; Banz Y; Oppliger-Leibundgut E; Fiedler M; Angelillo-Scherrer A; Rovo A; Bacher U
    Leuk Lymphoma; 2018 Sep; 59(9):2233-2237. PubMed ID: 29295644
    [No Abstract]   [Full Text] [Related]  

  • 19. Durable clinical and cytogenetic remission in an elderly patient with relapsed acute myeloid leukemia treated with low-dose lenalidomide.
    Basile FG
    Leuk Lymphoma; 2009 Apr; 50(4):653-5. PubMed ID: 19373666
    [No Abstract]   [Full Text] [Related]  

  • 20. Incidence of 17p deletions and TP53 mutation in myelodysplastic syndrome and acute myeloid leukemia with 5q deletion.
    Sebaa A; Ades L; Baran-Marzack F; Mozziconacci MJ; Penther D; Dobbelstein S; Stamatoullas A; Récher C; Prebet T; Moulessehoul S; Fenaux P; Eclache V
    Genes Chromosomes Cancer; 2012 Dec; 51(12):1086-92. PubMed ID: 22933333
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.